NERATINIB: 2,089 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
2,089
Total FAERS Reports
327 (15.7%)
Deaths Reported
609
Hospitalizations
2,089
As Primary/Secondary Suspect
26
Life-Threatening
9
Disabilities
Jul 17, 2017
FDA Approved
Prescription
Status
Yes
Generic Available
FDA Application: 208051 ·
Patent Expires: Oct 15, 2028 · First Report: 200103 · Latest Report: 20250825
What Are the Most Common NERATINIB Side Effects?
#1 Most Reported
Diarrhoea
1,193 reports (57.1%)
#2 Most Reported
Nausea
527 reports (25.2%)
#3 Most Reported
Fatigue
446 reports (21.3%)
All NERATINIB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 1,193 | 57.1% | 150 | 358 |
| Nausea | 527 | 25.2% | 56 | 150 |
| Fatigue | 446 | 21.4% | 71 | 118 |
| Off label use | 383 | 18.3% | 137 | 178 |
| Vomiting | 297 | 14.2% | 44 | 128 |
| Constipation | 267 | 12.8% | 23 | 67 |
| Decreased appetite | 245 | 11.7% | 62 | 93 |
| Death | 181 | 8.7% | 181 | 48 |
| Disease progression | 142 | 6.8% | 92 | 78 |
| Weight decreased | 132 | 6.3% | 55 | 55 |
| Dehydration | 129 | 6.2% | 12 | 75 |
| Abdominal pain | 114 | 5.5% | 19 | 29 |
| Headache | 110 | 5.3% | 6 | 38 |
| Dizziness | 96 | 4.6% | 6 | 32 |
| Abdominal pain upper | 95 | 4.6% | 6 | 26 |
| Asthenia | 95 | 4.6% | 18 | 36 |
| Dyspepsia | 94 | 4.5% | 29 | 29 |
| Rash | 92 | 4.4% | 2 | 11 |
| Hospitalisation | 88 | 4.2% | 15 | 87 |
| Cough | 80 | 3.8% | 38 | 51 |
Who Reports NERATINIB Side Effects? Age & Gender Data
Gender: 98.8% female, 1.2% male. Average age: 58.1 years. Most reports from: US. View detailed demographics →
Is NERATINIB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 0 |
| 2008 | 1 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 16 | 3 | 13 |
| 2012 | 2 | 0 | 1 |
| 2013 | 6 | 0 | 2 |
| 2014 | 5 | 0 | 1 |
| 2015 | 35 | 27 | 23 |
| 2016 | 57 | 26 | 38 |
| 2017 | 314 | 15 | 48 |
| 2018 | 236 | 51 | 106 |
| 2019 | 180 | 63 | 85 |
| 2020 | 160 | 48 | 70 |
| 2021 | 85 | 14 | 35 |
| 2022 | 72 | 5 | 29 |
| 2023 | 71 | 14 | 32 |
| 2024 | 48 | 12 | 26 |
| 2025 | 21 | 3 | 10 |
What Is NERATINIB Used For?
| Indication | Reports |
|---|---|
| Breast cancer | 714 |
| Breast cancer female | 417 |
| Product used for unknown indication | 280 |
| Her2 positive breast cancer | 274 |
| Breast cancer metastatic | 207 |
| Her-2 positive breast cancer | 88 |
| Neoplasm malignant | 20 |
| Metastatic neoplasm | 19 |
| Metastases to central nervous system | 15 |
| Off label use | 15 |
NERATINIB vs Alternatives: Which Is Safer?
NERATINIB vs NETARSUDIL
NERATINIB vs NETUPITANT\PALONOSETRON
NERATINIB vs NEULASTA
NERATINIB vs NEUPOGEN
NERATINIB vs NEUPRO
NERATINIB vs NEURONTIN
NERATINIB vs NEVIRAPINE
NERATINIB vs NEXAVAR
NERATINIB vs NEXIUM
NERATINIB vs NEXPLANON
Official FDA Label for NERATINIB
Official prescribing information from the FDA-approved drug label.